Orca-T

Orca Bio announced positive results from its pivotal Phase III Precision-T study evaluating Orca-T, an investigational allogeneic T-cell immunotherapy for various blood cancers including AML, ALL, and high-risk MDS.

The COVID-19 pandemic has fundamentally transformed oncology care delivery, with telemedicine emerging as a permanent fixture that improves access while presenting challenges in patient assessment and reimbursement.

Novel allogeneic immunotherapy Orca-T demonstrated increased expression of CD4-, FOXP3-, and Helios-positive T cells compared to conventional stem cell grafts in hematologic malignancy patients.

Orca Bio's investigational cell therapy Orca-T demonstrated statistically significant improvement in survival without moderate-to-severe chronic GvHD compared to standard stem cell transplants.

A phase Ib/II clinical trial led by Mount Sinai researchers demonstrates successful outcomes in combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma treatment.